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Abstract
Objective: Recent non-invasive prenatal testing (NIPT) technologies are based on next-generation sequencing (NGS). NGS
allows rapid and effective clinical diagnoses to be determined with two common sequencing systems: Illumina and Ion
Torrent platforms. The majority of NIPT technology is associated with Illumina platform. We investigated whether fetal
trisomy 18 and 21 were sensitively and specifically detectable by semiconductor sequencer: Ion Proton.
Methods: From March 2012 to October 2013, we enrolled 155 pregnant women with fetuses who were diagnosed as high
risk of fetal defects at Xiamen Maternal & Child Health Care Hospital (Xiamen, Fujian, China). Adapter-ligated DNA libraries
were analyzed by the Ion ProtonTM System (Life Technologies, Grand Island, NY, USA) with an average 0.36 sequencing
coverage per nucleotide. Average total raw reads per sample was 6.5 million and mean rate of uniquely mapped reads was
59.0%. The results of this study were derived from BWA mapping. Z-score was used for fetal trisomy 18 and 21 detection.
Results: Interactive dot diagrams showed the minimal z-score values to discriminate negative versus positive cases of fetal
trisomy 18 and 21. For fetal trisomy 18, the minimal z-score value of 2.459 showed 100% positive predictive and negative
predictive values. The minimal z-score of 2.566 was used to classify negative versus positive cases of fetal trisomy 21.
Conclusion: These results provide the evidence that fetal trisomy 18 and 21 detection can be performed with
semiconductor sequencer. Our data also suggest that a prospective study should be performed with a larger cohort of
clinically diverse obstetrics patients.
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Introduction
Prenatal screening and diagnostics for fetal chromosomal
aneuploidy are well established worldwide for pregnant women
[1,2]. Predictive testing during the first trimester includes a
combination of fetal ultrasound and maternal serum biomarkers
[3]. Women with fetuses at high risk of defects are also provided
opportunities for invasive diagnostic testing, such as chorionic
villus sampling (CVS) at 12 weeks of gestation and amniocentesis
at 15 weeks of gestation [4,5]. Although these invasive tests are
highly accurate, they are associated with iatrogenic pregnancy loss
[6].
The prevalence rate of the common aneuploidy, trisomy 21, is
around 1 in 500 in the group of women that request screening. In
contrast, 1 in 200 women who receive first-trimester screening
(FTS) are categorized as increased risk. The main reason that
many women avoid testing or screening is because they are aware
of the risks associated with invasive testing [7]. Further, FTS has
two serious limitations; FTS has a false-negative rate of 10–25%
and a restricted time-window of 11–13 gestational weeks [8–12].
After Lo et al. discovered fetal cell-free DNA (cffDNA) floating
in maternal blood [13], there have been concerted attempts to
perform non-invasive prenatal testing (NIPT) with cffDNA [14].
The cffDNA is originated from apoptotic trophoblasts in the
placenta [13]. On average, the amount of cffDNA in plasma from
a pregnant woman is approximately 10% during 10–22 weeks of
gestation but there is a large variance in the fraction of cffDNA
between individuals [15]. The typical cffDNA size is approxi-
mately 150 base pairs (bp) [16]. The half-life of cffDNA is very
short [17], and fetal DNA fragments of maternal blood are no
longer detectable after birth [18]. Despite these limitations, NIPT
consists of well-accepted and advanced technologies. NIPT has
two key clinical advantages compared with those of invasive
prenatal testing; it does not confer a risk of pregnancy loss, and can
be performed during early pregnancy. However, NIPT is not
currently considered to be fully diagnostic and requires invasive
testing to confirm positive results because the discordant NIPT
data for detecting chromosomal abnormality have resulted from
placental or maternal cell mosaicism [19–21]. To minimize this
problem, risk scores and multiple cut-offs have been often used for
NIPT services [14].
Recent NIPT technologies are based on next-generation
sequencing (NGS) [22–27]. NGS allows rapid and effective clinical
diagnostic testing with two commonly used systems, the Illumina
and Ion Torrent platforms. Ion Torrent, semiconductor sequenc-
ing platform, enables acquisition of sequencing data within 2 to 4
hours, thus the sequencer may provide an alternative clinical
sequencing service with a reduced turn-around time. The majority
of NIPT technology is associated with Illumina platform. Previous
NIPT studies with the Illumina platform report consistent data for
common aneuploidies, particularly trisomy 18 and 21; sensitivity
and specificity are each higher than 98% [22–26]. A recent study
reports the results for non-invasive detection of common fetal
trisomy 13, 18, and 21 with Ion Proton, a semiconductor
sequencer [27]. The sensitivity and specificity of the common
fetal aneuploidies (Trisomy 13, 18, and 21) are each higher than
98% [27]. However, more references of non-invasive fetal
aneuploidy detection with semiconductor sequencing platform
are required.
In our study, we performed NIPT for fetal trisomy 18 and 21
with Ion Proton. The testing results of semiconductor sequencing
platform have rarely been reported as an NIPT technology [27].
Therefore, we investigated whether fetal trisomy 18 and 21 were
sensitively and specifically detectable by Ion Proton.
Materials and Methods
Study Subjects
From March 2012 to October 2013, we enrolled 155 pregnant
women with fetuses who were diagnosed as high risk of fetal
defects at Xiamen Maternal & Child Health Care Hospital
(Xiamen, Fujian, China). 28 pregnant women (18.1%) were 12–16
weeks of gestation, 86 women (55.5%) were 17–21 weeks of
gestation, and 41 women with fetuses (26.5%) were more than 22
weeks of gestation. Pregnant women who were scheduled to
receive invasive diagnostic testing (Amniocentesis) for fetal
karyotyping were asked to donate a blood sample before having
the invasive test. Women who gave written informed consent
participated in the study if they were $ 19 years old and had a
singleton pregnancy with a gestational age of at least 12 weeks.
The institutional review board at Xiamen Maternal & Child
Health Care Hospital approved this study.
We used the results of standard prenatal aneuploidy screening
with individual risk scores and interpretations produced by
accredited clinical laboratories for sorting out high risk group of
fetal defects. First-trimester serum markers included pregnancy-
associated plasma protein A (PAPP-A) and free beta subunit or
total human chorionic gonadotropin (hCG). Second-trimester
serum markers included maternal serum alpha-fetoprotein
(MSAFP), hCG, unconjugated estriol, and inhibin A. First-
trimester serum markers were used in combination with
sonographic measurement of fetal nuchal translucency (combined
FTS test) to categorize patients into high or low risk groups.
Second-trimester serum values were evaluated alone (quadruple
screening test) or in combination with FTS results to define
aneuploidy risk. To determine fetal karyotypes, fetal cells from
amniotic fluid were cultured to test for chromosomal abnormalities
by the method of Barch et al [28]. Cytogenetic analysis performed
on all 155 fetal cells indicated that 139 (89.7%) were chromo-
somally normal, 5 (3.2%) were trisomy 18, and 11 (7.1%) were
trisomy 21.
Cell-free DNA Preparation and Sequencing
Eligible subjects were asked to participate in the study after
receiving counseling about the invasive diagnostic test. Approxi-
mately 10 mL of whole blood was collected from each subject and
placed in a Cell-Free DNA BCTTM tube (Streck, Omaha, NE,
USA) before the invasive procedure. Within 6 hours of collection,
the maternal blood samples were centrifuged first at 1,2006g for
15 min at 4uC. Plasma was transferred to microcentrifuge tubes,
centrifuged again at 16,0006g for 10 min at 4uC to remove
residual cells, transferred to fresh tubes, and stored at 280uC. For
each sample, plasma cfDNA was extracted from 1 mL of plasma
using the QIAamp Circulating Nucleic Acid Kit from Qiagen
(Hilden, Germany). The resulting plasma cfDNA was used as
input DNA to make a library for sequencing. End-repair of the
plasma cfDNA was performed with T4 DNA polymerase, Klenow
DNA polymerase, and T4 polynucleotide kinase. The adapter-
ligated DNA libraries were analyzed with the Ion ProtonTM
System (Life Technologies, Grand Island, NY, USA) with an
average 0.36sequencing coverage per nucleotide. Ion PITM Chip
Kit version 2.0 (Life Technologies) was used for cfDNA
sequencing and 10 cfDNA samples per chip were analyzed.
Average total raw reads per sample was 6.5 million and mean rate
of uniquely mapped reads was 59.0%.
Data Analysis
Raw reads with different lengths acquired from the Ion Torrent
Suite software trimmed from the 39 end by sequencing quality
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value of .15, and filtered by read length (,50 bp) and GC
contents (35%–45%). Duplicate reads were identified by Picard
(http://picard.sourceforge.net/) with the default parameters and
removed by in-house python script. The sequences were binned
for each sample according to the index and mapped to the
unmasked human genome sequence (hg19). We tested several
mapping software programs, including BWA [29], Bowtie [30],
and SOAP2 [31]. The results in this study were derived from the
BWA mapping analysis. All chromosomes were divided into
segments with a bin size of 300 kb to calculate z-score for fetal
trisomy 18 and 21 detection. For the 155 samples, we calculated
the z-score for each chromosome of each sample to examine fetal
aneuploidy with mapped reads for each sample, and mean
mapped reads and standard deviation (SD) of 139 euploid samples.
For example, the z-score of case 1 for chr21 could be calculated as
follows: z-scorechr21_case1 = (mapped reads of chr21case1 – mean
mapped reads of chr21euploid group)/(SD for mean mapped reads of
chr21euploid group). The minimal z-scores to classify negative versus
positive cases of trisomy based on interactive dot diagrams were .
2.459 for fetal trisomy 18 and .2.566 for fetal trisomy 21.
Sequence data has been deposited in the NIH short read archive
(SRA) with the following BioProject accession number:
SRP044689.
Statistical Analysis
Categorical variables were summarized with the number and
percentage of subjects. Continuous variables were described as
means with SD. Positive predictive value (PPV) and negative
predictive value (NPV) were calculated with standard formulas for
binomial distributions. Wilson’s interval method was used to
calculate 95% confidence intervals (CI). Interactive dot diagrams
were used to assign classifications according to the presence of fetal
aneuploidy. Analyses were performed with MedCalc version
12.1.4 (MedCalc Software bvba, Ostend, Belgium).
Results
Table 1 shows the demographic characteristics of the enrolled
participants in this study. The mean maternal age of this study
cohort was 30.7364.99 years (range 19–43 years). 28 pregnant
women (18.1%) received NIPT during 12–16 weeks of gestation,
86 women (55.5%) received testing during 17–21 weeks of
gestation, and 41 women with fetuses (26.5%) who were more
than 22 weeks of gestation received testing. The ratio of male
(50.3%) to female (49.7%) fetuses was nearly 1:1; however, in
aneuploidies, the ratio of male (81.3%) to female fetuses (13.8%)
was 13:3.
Figure 1 presents interactive dot diagrams for fetal trisomy 18
and 21 showed the minimal z-score values of 100% PPV and
NPV. For fetal trisomy 18, the minimal z-score value of 2.459
Table 1. Demographic characteristics of study subjects.
Demographic characteristics Euploid (n =139) T18 (n=5) T21 (n =11) Total (n =155)
Maternal age, years, mean6SD 30.6165.01 27.6065.50 33.6463.29 30.7364.99
$ 35 years (%) 36 (25.9) 1 (20.0) 5 (45.5) 42 (27.1)
NIPT during 12–16 gestational weeks (%) 25 (18.0) 1 (20.0) 2 (18.2) 28 (18.1)
NIPT during 17–21 gestational weeks (%) 78 (56.1) 4 (80.0) 4 (36.4) 86 (55.5)
NIPT $ 22 gestational weeks (%) 36 (25.9) 0 (0.0) 5 (45.5) 41 (26.5)
Male fetus (%) 65 (46.8) 4 (80.0) 9 (81.8) 78 (50.3)
Female fetus (%) 74 (53.2) 1 (20.0) 2 (18.2) 77 (49.7)
Z-score of chr18 (min, max) 23.184, 2.459 4.017, 10.193 21.730, 1.592 23.184, 10.193
Z-score of chr21 (min, max) 23.080, 2.566 21.449, 0.387 4.693, 30.943 23.080, 30.943
T18, Trisomy 18; T21, Trisomy 21; SD, standard deviation; NIPT, non-invasive prenatal testing.
doi:10.1371/journal.pone.0110240.t001
Figure 1. Interactive dot diagrams of trisomy 18 and 21. (A) Interactive dot diagram of trisomy 18. (B) Interactive dot diagram of trisomy 21.
doi:10.1371/journal.pone.0110240.g001
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showed 100% PPV and NPV. The minimal z-score of 2.566 was
used to classify negative versus positive cases of fetal trisomy 21.
Table 2 summarizes the PPVs and NPVs of the NIPT results for
fetal trisomy 18 and 21. For fetal trisomy 18, the PPV (95% CI:
47.8%–100.0%) and NPV (95% CI: 97.6%–100.0%) were 100%.
The PPV (95% CI: 71.5%–100.0%) and NPV (95% CI: 97.5%–
100.0%) for detecting fetal trisomy 21 were also 100%. On the
whole, the PPV (95% CI: 79.4%–100.0%) and NPV (95% CI:
97.4%–100.0%) of combined detection of fetal trisomy 18 and 21
were 100%.
Discussion
We have examined the feasibility of NIPT using cffDNA in a
predominantly high-risk obstetrics population using the semicon-
ductor sequencing system: Ion Proton. Fetal trisomy 18 and 21
were non-invasively detectable with 100% PPV and NPV. The
results of present study provide the evidence that non-invasive fetal
trisomy 18 and 21 detection can be performed with semiconductor
sequencing platform. However, our test is still far away from a
clinically validated test because there was not consideration for
plasma fetal DNA fraction.
According to previous reports, the Ion Torrent sequencer shows
equivalent performance to the Illumina platform [32–34]. Quail et
al. [32] measured Ion Torrent PGM data against Illumina
HiSeq2000 and MiSeq results, and found that the error rate of
Ion Torrent PGM data was 1.78%. In contrast, Illumina
HiSeq2000 and MiSeq platforms demonstrated error rates
ranging from 0.26% to 0.80%, and the rates of true single
nucleotide polymorphisms (SNPs) were higher for Ion Torrent
PGM analysis compared to that of the Illumina HiSeq2000 and
MiSeq analysis [32]. Boland et al. [33] demonstrated that Ion
Proton genotyping data were nearly concordant with SNP
microarray data; further, the concordance rates were similar to
those of the Illumina HiSeq2000 results. Chen et al. [34]
compared the performances of the Ion Proton and Illumina
MiSeq systems for ultra-low coverage sequencing. Ion Proton and
Illumina MiSeq platforms present similar coverage for relative
depth (RD) at each 1-Mbp of sequencing for GC-content. Both
sequencing systems correctly detected fetal tissue aneuploidies
[34]. Ion Proton system can construct ,80 million raw reads in 3–
4 hours, which allows chromosomal abnormality detection within
1–2 working days, is advantageous for applications that require
precise turn-around times, such as prenatal genetic screening [34].
Conventional noninvasive aneuploidy screening tests are not
straight forward. None of the screening tests are ideal, because
detection rates for chromosomal abnormalities are less than 100%.
By definition, the false-positive rate is 5% if modeled for a
common obstetrics population. Maternal serum marker and
ultrasound screening tests have been performed widely for over
a decade. These have been popular but have limitations. Henry et
al. [35] analyzed the birth of Down’s syndrome after routine
noninvasive screening largely replaced age-related invasive proce-
dures in Colorado from 1989 to 2005. Despite the increase in
prenatal screening, neonates with trisomy 21 increased in women
over 35 years of age. One explanation is that women did not
receive the recommended protocol, perhaps incorrectly assuming
that a single blood test would definitively detect abnormalities.
Serum biomarker analysis and ultrasound sonography do not
definitively detect chromosomal aneuploidy. A positive screen
result must be followed up with an invasive prenatal test (CVS or
amniocentesis) to determine whether fetal aneuploidy is truly
present. Previous studies of NIPT with cffDNA report consistently
accurate results for detecting common aneuploidies, particular
trisomy 18 and 21 [22–27]. However, the cost of the test is a major
issue. Currently, the cost of a plasma cffDNA test ranges from
about $800 to $2,000 in the US and from $500 to $1,500 in other
countries [14]. Two previously published reports have estimated
costs when the cfDNA test is applied to women with positive
conventional screening results [36,37]. They concluded that
applying the cfDNA test was connected to a net cost reduction
in comparison with CVS or amniocentesis [36,37].
In summary, we investigated whether fetal trisomy 18 and 21
could be detected by noninvasive Ion Torrent sequencing as has
previously been published for Illumina sequencing. However, the
present study has several limitations. First, our sample size was
smaller than other obstetrics populations in previous reports [22–
27]. The lower 95% CIs for NPV were almost 97.0% in our study,
whereas other studies usually demonstrate .98.0% of the lower
95% CIs for specificity. More than 400 high-risk pregnant women
will need to be enrolled in future studies to estimate.98.0% of the
lower 95% CIs for NPV or specificity with Wilson’s interval
method. Second, we did not find any positive cases for rare
chromosomal abnormalities, such as trisomy 9, trisomy 13, and sex
chromosome aneuploidies. Third, the participation rates for low-
risk pregnant women after serum biomarker testing and
ultrasound sonography did not reach expected levels. Fourth, we
could not measure Ion Proton sequencing data against data that
were analyzed by Illumina HiSeq or MiSeq due to insufficient
quantities of blood samples. Although the results of our study
provide initial evidence for NIPT of fetal trisomy 18 and 21 using
the semiconductor sequencing system, a prospective study on a
larger cohort of clinically diverse obstetrics participants is
warranted to validate these findings.
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Table 2. Positive predictive and negative predictive values in this study.
Aneuploidy Positive predictive value (95% CI) Negative predictive value (95% CI)
T18 (n = 5) 100.0% (47.8%–100.0%) 100.0% (97.6%–100.0%)
T21 (n = 11) 100.0% (71.5%–100.0%) 100.0% (97.5%–100.0%)
Combined detection (n = 16) 100.0% (79.4%–100.0%) 100.0% (97.4%–100.0%)
T18, trisomy 18; T21, trisomy 21.
doi:10.1371/journal.pone.0110240.t002
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